Cancers 2011, 3(1), 17-42; doi:10.3390/cancers3010017

Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics

1email, 1,2,* email and 2email
1 Biomedical Engineering and Technology Institute, Institutes for Advanced Interdisciplinary Research, East China Normal University, 3663 North Zhongshan Road, Shanghai, 200062, China 2 Biomedical Group, Nitto Denko Technical Corporation, 501 Via Del Monte, Oceanside, CA 92058, USA
* Author to whom correspondence should be addressed.
Received: 12 November 2010; in revised form: 10 December 2010 / Accepted: 22 December 2010 / Published: 23 December 2010
(This article belongs to the Special Issue Nanotechnology and Cancer Therapeutics)
PDF Full-text Download PDF Full-Text [692 KB, uploaded 23 December 2010 11:52 CET]
Abstract: The concept of utilizing polymers in drug delivery has been extensively explored for improving the therapeutic index of small molecule drugs. In general, polymers can be used as polymer-drug conjugates or polymeric micelles. Each unique application mandates its own chemistry and controlled release of active drugs. Each polymer exhibits its own intrinsic issues providing the advantage of flexibility. However, none have as yet been approved by the U.S. Food and Drug Administration. General aspects of polymer and nano-particle therapeutics have been reviewed. Here we focus this review on specific clinically relevant anticancer polymer paclitaxel therapeutics. We emphasize their chemistry and formulation, in vitro activity on some human cancer cell lines, plasma pharmacokinetics and tumor accumulation, in vivo efficacy, and clinical outcomes. Furthermore, we include a short review of our recent developments of a novel poly(L-g-glutamylglutamine)-paclitaxel nano-conjugate (PGG-PTX). PGG-PTX has its own unique property of forming nano-particles. It has also been shown to possess a favorable profile of pharmacokinetics and to exhibit efficacious potency. This review might shed light on designing new and better polymer paclitaxel therapeutics for potential anticancer applications in the clinic.
Keywords: polymer paclitaxel therapeutics; polymeric micelles; polymer paclitaxel conjugates

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Yang, D.; Yu, L.; Van, S. Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics. Cancers 2011, 3, 17-42.

AMA Style

Yang D, Yu L, Van S. Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics. Cancers. 2011; 3(1):17-42.

Chicago/Turabian Style

Yang, Danbo; Yu, Lei; Van, Sang. 2011. "Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics." Cancers 3, no. 1: 17-42.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert